Business context and reporting period
The supplied filing is Aikido Pharma Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2022—not a filing for Dominari Holdings Inc. Aikido describes itself as a development-stage biotechnology company, with preclinical oncology and antiviral programs, alongside a growing portfolio of outside-company investments. Its principal programs include pancreatic cancer, AML/ALL, and broad-spectrum antivirals.
Financial results and position
Amounts below are in U.S. dollars; financial statement amounts are generally in thousands, except per-share data.
| Metric | Q1 2022 | Q1 2021 / prior date |
|---|---|---|
| Revenue | No material revenue; management reports little or none in the last two years | No material revenue |
| Operating expenses | $3.803 million | $2.318 million |
| Operating loss | $3.803 million | $2.318 million |
| Net loss | $3.535 million | $3.962 million |
| Net loss attributable to common shareholders | $6.544 million, including $3.009 million of deemed preferred-stock dividends | $3.962 million |
| Basic and diluted loss per share | $0.07 | $0.07 |
| Net cash used in operating activities | $3.836 million | $1.053 million |
| Cash and cash equivalents | $49.686 million | $65.562 million at December 31, 2021 |
| Restricted cash | $20.953 million | None reported |
| Working capital | Approximately $98.3 million | Not stated for the comparable date |
| Total liabilities | $0.895 million | $1.061 million at December 31, 2021 |
Total assets were $117.946 million, including $14.435 million of marketable securities, $18.610 million of long-term investments, and $9.310 million of notes receivable at fair value. The filing reports no borrowings or debt balance. The preferred-stock proceeds include $20.953 million held in escrow and released to the company only upon conversion. No operating margin is meaningful given the absence of revenue.
Material changes versus the prior comparable period
- Operating expenses rose 64% to $3.803 million. General and administrative expense increased $0.575 million, while research and development expense increased to $2.016 million from $0.072 million; the prior period included $1.034 million of acquired-license expense that did not recur.
- Net loss improved to $3.535 million from $3.962 million, principally as other income/expense shifted to $0.268 million of income from $1.644 million of expense. This reflected a smaller marketable-securities loss and a favorable change in investment fair value.
- Operating cash use increased to $3.836 million from $1.053 million. Investing cash use was $10.078 million versus $71.754 million; financing provided $18.991 million versus $78.073 million.
- The company raised approximately $21.9 million gross through Series O and Series P preferred offerings, with $18.991 million reported as net financing proceeds. Each series is convertible into 11 million common shares at $1.00 per share, subject to adjustments; the offering also included 1.76 million placement-agent warrants.
- Long-term investments increased to $18.610 million from $9.465 million, reflecting purchases and valuation changes. Management recorded a $1.4 million unrealized gain on Tevva Motors, a material contributor to investment-related results.
Outlook, risks and unusual items
- No revenue or earnings guidance is provided. Management expects no revenue until a biotechnology product is fully developed, potentially for many years, and says advancing its preclinical programs will require additional resources and ultimately third-party capital.
- The filing contains conflicting liquidity statements: Note 2 says cash is adequate for at least the next 12 months, while MD&A says there is substantial doubt about the company’s ability to continue as a going concern within one year. MD&A also says success depends on obtaining financing and generating sufficient cash flow.
- The principal drug programs remain preclinical. The company had not submitted an IND or NDA for DHA-dFdC; animal studies are required before an IND. Development, manufacturing scale-up, regulatory approval, and clinical success remain uncertain. The company’s expected use of the FDA’s 505(b)(2) pathway is a plan, not an approval or assurance of a shorter process.
- Management says COVID-19 previously slowed drug development and acquisitions; it viewed those effects as easing but noted that potential financial and development impacts were not readily determinable.
- Investment valuations and liquidity are risks: the portfolio includes private-company and other Level 3 assets, while notes receivable totaling $9.310 million are also valued using significant unobservable inputs. Results include fair-value movements that may not represent cash gains.
- Disclosure controls were deemed ineffective at March 31, 2022 due to material weaknesses, including insufficient segregation of duties and controls to ensure material transactions and developments are reflected in the financial statements.
- The company reported no material active or pending legal proceedings and no off-balance-sheet arrangements. It reported no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm the issuer: the provided text identifies Aikido Pharma Inc. (ticker AIKI), despite the request metadata naming Dominari Holdings Inc.
- Reconcile the conflicting 12-month liquidity and going-concern statements, including the availability and release conditions of the $20.953 million in restricted cash.
- Review preferred-stock conversion, redemption rights, and potential dilution: the two series represent up to 22 million common shares, in addition to outstanding warrants and options.
- Assess the quality, valuation methods, concentration, and liquidity of private investments and fair-value notes receivable, and the effect of noncash gains on reported results.
- Track cash burn, future financing needs, and remediation of the disclosed material weaknesses in financial reporting controls.
- Verify R&D milestones, manufacturing progress, required animal studies, and any subsequent IND or regulatory submissions; the filing reports no IND or NDA had been submitted as of its discussion.